Drug intelligence / Profile preview

losartan or hydrochlorothiazide

Development stage
Approved
Lead developer
Merck
Modality
Small Molecules
Administration
Oral
01

Overview

This entry refers to two distinct pharmaceutical drugs, losartan and hydrochlorothiazide, which are commonly used in the management of cardiovascular conditions, particularly hypertension. Losartan is an angiotensin II receptor blocker (ARB) that works by selectively blocking the binding of angiotensin II to the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide is a thiazide diuretic that acts by inhibiting the sodium-chloride cotransporter in the distal convoluted tubules of the kidneys, resulting in increased excretion of sodium, chloride, and water, thereby reducing blood volume and blood pressure. These drugs are often prescribed individually or in fixed-dose combinations for blood pressure control and other related indications.

Brand names
CozaarHydrodiurilMicrozideOreticAquazideEsidrexHydrazideThiazideBpzideHctzAgrozideHydronolHydrozideHychlorzide
Other names
losartan potassiumHCTZHCT
02

Targets

SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)AGTR1 (Angiotensin II Type-1 receptor)URAT1 (Uric Acid Transporter 1)

Beyond the preview

Go deeper on losartan or hydrochlorothiazide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on losartan or hydrochlorothiazide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call